Location History:
- North Bethesda, MD (US) (2020)
- Rockville, MD (US) (2020)
Company Filing History:
Years Active: 2020
Title: Yuriy Gusev: Innovator in Genetic Research and Personalized Oncology
Introduction
Yuriy Gusev is a notable inventor based in North Bethesda, MD (US), recognized for his contributions to the fields of genetic research and personalized medicine. With a total of two patents to his name, Gusev's work focuses on understanding memory impairment and enhancing cancer treatment through innovative platforms.
Latest Patents
Gusev's latest patents include "Genetic markers for memory loss" and "Systems medicine platform for personalized oncology." The first patent relates to methods for determining an individual's risk of memory impairment by analyzing gene expression profiles from peripheral blood leukocytes. This method allows for the identification of individuals at increased risk compared to normal individuals. The second patent introduces a web-based platform that integrates patient characteristics and clinical outcome data with high-throughput research data. This platform facilitates systems medicine by enabling the identification of trends in integrated datasets, ultimately supporting better-targeted therapies for cancer.
Career Highlights
Throughout his career, Gusev has worked with prestigious institutions such as Georgetown University and the University of Rochester. His research has significantly contributed to the understanding of genetic factors in health and disease, particularly in the context of memory loss and oncology.
Collaborations
Gusev has collaborated with esteemed colleagues, including Massimo S Fiandaca and Mark E Mapstone. These collaborations have further enriched his research and innovation efforts.
Conclusion
Yuriy Gusev's work exemplifies the intersection of genetics and personalized medicine, showcasing his commitment to advancing healthcare through innovative research. His patents reflect a dedication to improving patient outcomes and understanding complex health issues.